Healthcare Value Capital, LLC
Reported holdings as of Q3 2021, from 12 quarterly filings.
This filer last reported in Q3 2021; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ALKERMES PLC OPT | ALKS | $6.2M | 100,000 | +4.85pp | 3q | -33.3%-$3.1M | |
| PFIZER INC OPT | PFE | $5.4M | 75,000 | +2.81pp | 3q | -25.0%-$1.8M | |
| GILEAD SCIENCES INC | GILD | $4.2M | 60,000 | -2.02pp | 11q | -20.0%-$1.0M | |
| GLAXOSMITHKLINE PLC | GSKXXXX | $3.8M | 100,000 | -0.39pp | 12q | HELD | |
| AMRYT PHARMA PLC | AMYT | $3.0M | 250,000 | +1.13pp | 3q | +25.0%+$604.6K | |
| MERCK & CO INC | MRK | $3.0M | 40,000 | -0.27pp | 3q | HELD | |
| ASTRAZENECA PLC | AZN | $3.0M | 50,000 | -0.04pp | 3q | HELD | |
| BRISTOL-MYERS SQUIBB CO | BMY | $3.0M | 50,000 | -0.82pp | 3q | HELD | |
| PROSHARES TR OPT | SPXUXXXX | $2.6M | options only | +3.38pp | 3q | OPTIONS | |
| IRONWOOD PHARMACEUTICALS INC | IRWD | $2.6M | 200,000 | -1.26pp | 3q | HELD | |
| CLOVIS ONCOLOGY INC | CLVSQ | $2.2M | 500,000 | -1.38pp | 9q | HELD | |
| TYME TECHNOLOGIES INC | TYME | $2.1M | 2,000,000 | +0.30pp | 12q | +33.3%+$515.0K | |
| ANTARES PHARMA INC | ATRS | $1.8M | 500,000 | -0.75pp | 12q | HELD | |
| PROSHARES TR OPT | SQQQXXXX | $1.7M | options only | +1.59pp | 2q | OPTIONS | |
| PROSHARES TR II OPT | UVXYXXXX | $1.2M | options only | - | new | OPTIONS | |
| AMARIN CORP PLC OPT | AMRNXXXX | $1.0M | options only | +0.27pp | 7q | OPTIONS | |
| VERTEX PHARMACEUTICALS INC | VRTX | $907.0K | 5,000 | - | new | NEW | |
| GREENLANE HLDGS INC | GNLNXXXX | $830.0K | 350,000 | -1.48pp | 10q | HELD | |
| VYNE THERAPEUTICS INC | VYNE | $556.0K | 400,000 | -2.05pp | 3q | -11.1%-$69.5K | |
| ADAMAS PHARMACEUTICALS INC | ADMS | $491.0K | 100,000 | -0.08pp | 5q | HELD | |
| GAMIDA CELL LTD | GMDAQ | $392.0K | 100,000 | -0.18pp | 4q | +33.3%+$98.0K | |
| DURECT CORP | DRRX | $320.0K | 250,000 | - | new | NEW | |
| PROSHARES TR II OPT | VIXYXXXX | $285.0K | options only | -0.64pp | 2q | OPTIONS |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $28.2M | 55.7% |
| Not classified | $22.4M | 44.3% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q3 2021 | $50.7M | 23 | 3 | 3 | 4 | 2 | 72.6% | 46 |
| Q2 2021 | $50.2M | 22 | 3 | 9 | 0 | 2 | 69.2% | 47 |
| Q1 2021 | $44.9M | 21 | 11 | 2 | 1 | 7 | 67.5% | 47 |
| Q4 2020 | $29.7M | 17 | 1 | 1 | 1 | 1 | 82.0% | 47 |
| Q3 2020 | $30.3M | 17 | 5 | 2 | 1 | 5 | 85.7% | 47 |
| Q2 2020 | $39.2M | 17 | 0 | 4 | 5 | 6 | 78.4% | 45 |
| Q1 2020 | $59.5M | 23 | 10 | 6 | 3 | 1 | 67.5% | 45 |
| Q4 2019 | $34.0M | 14 | 0 | 2 | 3 | 4 | 88.1% | 45 |
| Q3 2019 | $55.4M | 18 | 6 | 0 | 3 | 5 | 83.8% | 45 |
| Q2 2019 | $53.3M | 17 | 9 | 3 | 1 | 1 | 85.5% | 45 |
| Q1 2019 | $26.0M | 9 | 3 | 2 | 0 | 3 | 100.0% | 44 |
| Q4 2018 | $25.7M | 9 | 0 | 0 | 0 | 0 | 100.0% | 44 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.